Grand Brilliance Group Holdings Limited reported revenue of approximately HK$52.5 million for the six months ended 30 September 2025, reflecting an increase of about 25.9% from HK$41.7 million in the same period last year. The growth was partly attributed to winning certain tenders for supplying medical devices in hospital expansion projects. Gross profit stood at HK$21.5 million, compared with HK$20.4 million previously, while gross margin narrowed to 40.9% from 48.9%.

Administrative and other operating expenses rose to about HK$17.5 million from HK$16.8 million, partly due to increased marketing initiatives and higher general wages. Overall, profit for the period grew from HK$3.4 million to approximately HK$3.9 million. Basic and diluted earnings per share were HK0.51 cent, compared with HK0.42 cent in the prior period.

As of 30 September 2025, the Group held around HK$52.9 million in cash and cash equivalents, with no material debt financing. There were no major acquisitions, disposals, or significant capital commitments during the reporting period. The Board resolved not to declare an interim dividend for the six months ended 30 September 2025.